Risk for pulmonary embolism was higher than that of isolated deep vein thrombosis in SCT<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Sept. 12, 2024 (HealthDay News) — Individuals with sickle cell trait (SCT) have an increased risk for venous thromboembolism (VTE), according to a study published online Sept. 12 in Blood Advances<\/em>.<\/p>\n Keng-Han Lin, Ph.D., from 23andMe in Sunnyvale, California, and colleagues leveraged data from the 23andMe Research cohort (4,184,082 participants) to calculate the ancestry-independent risk for VTE associated with SCT. A meta-analysis of three genetic ancestry groups (European [3,183,142 participants], Latine [597,539 participants], and South Asian [41,257 participants]) was used to calculate odds ratios.<\/p>\n The researchers found that 2.25 percent of participants from the full cohort reported a history of VTE. In a meta-analysis, the risk for VTE was increased 1.45-fold among individuals with SCT versus non-SCT carriers, similar to the full cohort estimate. In SCT, the risk for pulmonary embolism (PE) was higher than that of isolated deep vein thrombosis (DVT; odds ratios, 1.95 versus 1.04). Carriers of factor V Leiden had a 3.30-fold increased risk for VTE versus noncarriers, with a higher risk for isolated DVT versus PE (odds ratios, 3.59 and 2.72, respectively).<\/p>\n “Our study also provides high-powered data to confirm the PE-predominant pattern of VTE in SCT carriers. These data may inform clinical practice guidelines, future research, and public health initiatives in SCT,” the authors write.<\/p>\n Several authors are employed by and hold stock or stock options in 23andMe.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n